Even though the third-generation inhibitorosimertinib representsa valid therapeutic option for NSCLC patients, the occurrence of newmutations, including C797S, is responsible for the loss of effectivenessof osimertinib and other EGFR inhibitors in lung cancer therapies.For this reason, the search for inhibitors able to covalently bindthe catalytic Lys745 has emerged as a promising approach to identifyfourth-generation EGFR inhibitors for the treatment of NSCLC patients. This evidence concerns the gene EGFR and lung carcinoma.